India, Sept. 11 -- Biotech and healthcare saw regulatory approvals, strategic partnerships, M&A activity, and a steady stream of clinical trial updates driving investor attention.
Notable developments include Axogen's planned acquisition of BioCircuit Technologies, Bluejay Diagnostics' partnership with Lovell Government Services, positive data from Roivant, AstraZeneca, Structure Therapeutics, and Pharvaris, and a Phase 3 miss for Novartis' del-desiran.
Let's dive into the details... FDA Approvals
JNJ Expands Eye Care Portfolio
Johnson & Johnson (JNJ) received CE Marking for its ACUVUE OASYS MAX 2-Week reusable contact lenses, designed to improve comfort and clarity for patients facing increased screen time and blue-violet light exposur...